<DOC>
	<DOC>NCT00349752</DOC>
	<brief_summary>The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease. Subjects had to be in remission (CDAI&lt;=150) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.</brief_summary>
	<brief_title>Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Men and women Age 18 years or older with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) score of ≥ 220 ≤450) Active or draining fistula present at screening Lactating and/or pregnant female subjects A history of any health condition that could potentially interfere with the disease and/or the treatment A history of an adverse reaction to polyethylene glycol (PEG) or a protein medicinal product Any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study History of drug or alcohol abuse in the prior year Receipt of any experimental therapy within or outside a clinical trial in the 3 months prior to Visit 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Crohn's Disease</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>